Cidara Therapeutics, Inc. announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023. The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 - 15, 2023. Janssen recently delivered its Election to Proceed Notice for CD388 with the intent to transfer its rights and obligations to another entity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.21 USD | -6.58% | -7.81% | -29.41% |
May. 15 | Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M | MT |
Apr. 25 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.41% | 51.14M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CDTX Stock
- News Cidara Therapeutics, Inc.
- Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023